CDC: Cancer Death Rates in Youth Continued to Decline Through 2021
By Elana Gotkine HealthDay Reporter
THURSDAY, Nov. 16, 2023 -- Cancer death rates in youth ages 0 to 19 years continued to decline during 2001 to 2021, according to a November data brief published by the U.S. Centers for Disease Control and Prevention National Center for Health Statistics.
Sally C. Curtin, and Robert N. Anderson, Ph.D., from the National Center for Health Statistics in Hyattsville, Maryland, present trends in cancer death rates for 2001 to 2021 for youth ages 0 to 19 years, by age and for White, Black, and Hispanic youth.
The researchers found that the cancer death rate for youth ages 0 to 19 years in the United States decreased 24 percent from 2001 to 2021, from 2.75 to 2.10 per 100,000. Decreases in cancer death rates were seen for all age groups between 2001 and 2011 (0 to 4, 5 to 9, 10 to 14, and 15 to 19), but declines through 2021 were only seen for rates among those ages 0 to 4 and 5 to 9. Between 2001 and 2011, declines in cancer death rates were seen for Black non-Hispanic, White non-Hispanic (White), and Hispanic youth; the decline continued through 2021 for White youth only. The most common cancer causing death in youth in 2021 was brain cancer, with a higher rate than that for leukemia and bone and articular cartilage cancer (0.59 versus 0.48 and 0.25, respectively, per 100,000 youth).
"The overall cancer death rate declined by one-fourth during 2001 to 2021, with a greater percentage decline for females (30 percent) than males (19 percent)," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-11-17 10:24
Read more
- Prevalence of Diabetes 15.8 Percent in U.S. Adults From 2021 to 2023
- 1 in 5 People Could Have Long COVID
- July 2019 to June 2023 Saw Increase in OD Deaths With Ketamine Detected
- FDA Approves Aucatzyl (obecabtagene autoleucel) for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Blood Test Might Spot Women in Labor at Risk for Preeclampsia
- Orexo initiates new study of OX640 in participants with allergic rhiniti
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions